Mansukhani S, Shah I

Idioma: Ingles.
Referencias bibliográficas: 22
Paginas: 96-99
Archivo PDF: 71.87 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289-302.

2. Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005; 20: 1745-52.

3. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from firstline antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-7.

4. Weisiger RA. Isoniazid Hepatotoxicity. [Online] 2007 Jun 21; Available from: URL:http://emedicine.medscape.com/ article/180554-overview

5. Ohkawa K, Hashiguchi M, Ohno K, Kiuchi C, Takahashi S, Kondo S, et al. Risk factors for antituberculous chemotherapy- induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther 2002; 72: 220-6.

6. Gendrel D, Nardou M, Mouba JF, Gahouma D, Moussavou A, Boguikouma JB. Hepatotoxicity of the combination of isoniazid- rifampicin in African children. Role of malnutrition and HB virus. Arch Fr Pediatr 1989; 46: 645-8.

7. Consensus Statement of IAP Working Group. Treatment of childhood tuberculosis: Indian Academy of Pediatrics. Indian Pediatr 1997; 34: 1093-6.

8. Chopra K. Short course chemotherapy in childhood tuberculosis. Indian Pediatr 1995; 32: 625-8.

9. Khadilkar VV, Khadilkar AV, Choudhury P, Agarwal KN, Ugra D, Shah NK. IAP growth monitoring guidelines for children from birth to 18 years. Indian Pediatr 2007; 44: 187-97.

10. Corrigan D, Paton J. Hepatic enzyme abnormalities in children on triple therapy for tuberculosis. Pediatr Pulmonol 1999; 27: 37-42.

11. Kabra SK, Lodha R, Seth V. Category based treatment of tuberculosis in children. Indian Pediatr 2004; 41: 927-37.

12. Tsagaropoulou-Stinga H, Mataki-Emmanouilidou T, Karida- Kavalioti S, Manios S. Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin. Pediatr Infect Dis 1985; 4: 270-3.

13. Weisiger RA. Isoniazid Hepatotoxicity. [Online] 2007 Jun 21. Available from: URL:http://emedicine.medscape.com/ article/180554-overview

14. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.

15. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-6.

16. Døssing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996; 77: 335-40.

17. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004; 38: 1074-9.

18. Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol 2003; 41: 1226-32.

19. Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71: 359-62.

20. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-6.

21. Reto Valiente LV, Castillo Vergara J, Pichilingue Reto P, Pichilingue Prieto OA. Hepatotoxicity caused by antituberculosis drugs in pediatrics. Rev Gastroenterol Peru 2005; 25: 362-5.

22. Guidance for national tuberculosis programs on the management of tuberculosis in children. [Online] 2006. Available from: URL: http://whqlibdoc.who.int/hq/2006/ WHO_HTM_TB_2006.371_eng.pdf Accessed on 18th February 2009